Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192192 · ClinicalTrials.gov registry record · Phase 3
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults
A Phase 3 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00192192 is a Phase 3 study that has completed, run by MedImmune. The registered enrollment target is 20 participants.
The verdict
NCT00192192, a Phase 3 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
To perform a variety of assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live, cold-adapted (liquid CAIV-T; Wyeth Lederle Vaccines, Marietta, PA).
Interventions
- BIOLOGICAL CAIV-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2000-11 |
| Est. Completion | 2000-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192192
The ClinicalTrials.gov registry entry for NCT00192192 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAIV-T is the first listed.
NCT00192192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192192 about?
NCT00192192 is a clinical study titled "Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults". To perform a variety of assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live, cold-adapted ...
What is the current status of trial NCT00192192?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2000-11. Estimated completion is 2000-12.
What interventions are being tested in trial NCT00192192?
The interventions under investigation include: CAIV-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192192?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.